Annual Report 2024
Department of Hepatobiliary and Pancreatic Oncology
Takuji Okusaka, Hideki Ueno, Chigusa Morizane, Susumu Hijioka, Yoshikuni Nagashio, Yuta Maruki, Shota Harai, Shin Yagi, Yasuhiro Komori
Introduction
The Department of Hepatobiliary and Pancreatic Oncology treats tumors originating from the liver, biliary system or pancreas, including hepatocellular carcinoma (HCC), biliary tract cancer and pancreatic cancer. We work closely with surgeons and radiologists who have special expertise in these areas as part of the multi-disciplinary care given at the National Cancer Center Hospital (NCCH). We also conduct clinical and translational research on hepatobiliary and pancreatic tumors and aim to develop new and more effective diagnostic methods and treatments.
The Team and What We Do
The department consists of seven staff oncologists and several residents. We have used percutaneous ablation therapy for most patients with three or fewer HCC nodules, all of which are smaller than 3 cm in diameter. We also perform transcatheter arterial chemoembolization (TACE), mainly with patients with multiple HCC nodules. Systemic or intra-arterial chemotherapeutic regimens are indicated in patients with advanced HCC for whom locoregional intervention and surgery are unsuitable or have been unsuccessful. In patients with unresectable pancreatic cancer or biliary tract cancer, chemotherapy is performed in clinical practice or as a clinical trial to develop new treatment. We have actively introduced endoscopic procedures for imaging diagnosis (endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP)), tumor biopsy (EUS-guided tissue acquisition (EUS-TA)), and biliary drainage (including EUS-guided hepaticogastrostomy (EUS-HGS) and EUS-guided choledochoduodenostomy (EUS-CDS)) (Tables 1 and 2).
Table 1. Number of cancer patients
Research Activities
We published 22 papers as a first author in peer-reviewed journals in 2024.
Clinical Trials
Forty-eight clinical studies are ongoing, including six phase I studies, six phase II studies, and twelve phase III studies, such as neoadjuvant chemotherapy before resection versus upfront surgery alone for patients with resectable tumors, chemotherapy with a new regimen versus standard therapy for patients with advanced tumors, and several observation or registration trials. Our studies are supported by the National Cancer Center Research and Development Fund (2023-J-03), Project for Development of Innovative Research on Cancer Therapeutics (24ck0106835h0002, 24ck0106808h0002, 24ck0106864h0002, 24lk0221182h0002, 24lk0201159h0003) from the Japan Agency for Medical Research and Development.
Education
Our staff members are working closely with residents to support their skill development and knowledge expansion in both clinical and research fields. We conduct conferences daily for clinical practice and weekly for research development. The residents in our department published 15 papers as a first author in peer-reviewed journals in 2024, and are performing 22 planning-stage or ongoing studies as a leading researcher, with assistance from staff members.
Future Prospects
Our department will continue to provide the best and latest diagnosis, treatment and supportive care, and develop more effective methods and techniques for all patients with hepatobiliary and pancreatic cancer in this country and all over the world. Among these, conducting clinical trials with novel promising agents for this disease is considered one of the most important tasks, and establishing cutting-edge endoscopic procedures in this field is the most significant mission for us.
List of papers published in 2024
Journal
1. Maruki Y, Hijioka S, Yagi S, Takasaki T, Chatto M, Fukuda S, Yamashige D, Okamoto K, Agarie D, Hara H, Hagiwara Y, Nagashio Y, Morizane C, Sone M, Okusaka T, Saito Y. Sedative effects of propofol and risk factors for excessive sedation in the endoscopic treatment of biliary and pancreatic diseases. DEN open, 5:e417, 2025
2. Muramatsu S, Ogura K, Morizane C, Satake T, Toda Y, Iwata S, Kobayashi E, Higashi T, Ikeuchi M, Kawai A. Statistics of Visceral Sarcoma in Japan: Report From the Population-Based National Cancer Registry (NCR) in Japan. Journal of surgical oncology, 131:274-284, 2025
3. Okuno T, Morizane C, Mizusawa J, Yanagimoto H, Kobayashi S, Imaoka H, Terashima T, Kawakami H, Sano Y, Okusaka T, Ikeda M, Ozaka M, Miwa H, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Sano K, Tobimatsu K, Katanuma A, Gotoh K, Yamaguchi H, Ishii H, Furuse J, Ueno M. Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113. International journal of clinical oncology, 30:83-91, 2025
4. Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, Hara H, Yabusaki H, Miyamoto A, Iwasa S, Muto M, Takashima T, Minashi K, Komatsu Y, Nishina T, Nakajima TE, Takeno A, Moriwaki T, Furukawa M, Sahara T, Ikezawa H, Nomoto M, Takashima S, Uehara T, Funasaka S, Yashiro M, Furuse J. Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study. Cancer science, 116:192-203, 2025
5. Itonaga M, Ogura T, Isayama H, Takenaka M, Hijioka S, Ishiwatari H, Ashida R, Okuda A, Fujisawa T, Minaga K, Takeshita K, Yamashita Y, Nishioka N, Ishii S, Omoto S, Ohtsuka T, Sofue K, Yasuda I, Shimokawa T, Kitano M. Usefulness of a dedicated laser-cut metal stent with an anchoring hook and thin delivery system for EUS-guided hepaticogastrostomy in malignant biliary obstruction: a prospective multicenter trial (with video). Gastrointestinal endoscopy, 101:970-978, 2025
6. Yamashige D, Hijioka S, Nagashio Y, Maruki Y, Komori Y, Kuwada M, Fukuda S, Yagi S, Okamoto K, Agarie D, Chatto M, Morizane C, Ueno H, Sugawara S, Sone M, Saito Y, Okusaka T. Metal stent versus plastic stent in endoscopic ultrasound-guided hepaticogastrostomy for unresectable malignant biliary obstruction: Large single-center retrospective comparative study. Digestive endoscopy, 37:117-129, 2025
7. Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. Journal of gastroenterology, 60:356-367, 2025
8. Ogata D, Namikawa K, Nakano E, Fujimori M, Uchitomi Y, Higashi T, Satake T, Morizane C, Yamazaki N, Kawai A. Comprehensive epidemiology of melanoma at all sites: insights from Japan's National Cancer Registry, 2016-2017. International journal of clinical oncology, 30:194-198, 2025
9. Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T, Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. Journal of gastroenterology, 60:368-369, 2025
10. Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kobayashi E, Higashi T, Kawai A. Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Japanese journal of clinical oncology, 55:490-497, 2025
11. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective. Japanese journal of clinical oncology, 55:465-476, 2025
12. Yamashige D, Hijioka S, Nagashio Y, Maruki Y, Fukuda S, Yagi S, Okamoto K, Hara H, Hagiwara Y, Agarie D, Takasaki T, Ohba A, Kondo S, Morizane C, Ueno H, Sone M, Saito Y, Okusaka T. Potential of 6-mm-diameter fully covered self-expandable metal stents for unresectable malignant distal biliary obstruction: a propensity score-matched study. Clinical endoscopy, 58:121-133, 2025
13. Yachida S, Yoshinaga S, Shiba S, Urabe M, Tanaka H, Takeda Y, Shimizu A, Sakamoto Y, Hijioka S, Haba S, Ashida R, Kushiyama Y, Asano K, Kobayashi M, Murawaki Y, Onishi K, Yamashita T, Kimura H, Totoki Y, Kamada H, Isomoto H, Hattori S, Morizane C, Ohkawa K, Kitano M, Hara K, Ikezawa K, Hanada K, Matsumoto K. KRAS Mutations in Duodenal Lavage Fluid after Secretin Stimulation for Detection of Pancreatic Cancer. Annals of surgery, 2025
14. Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. Update for: New developments in systemic therapy for advanced biliary tract cancer. Japanese journal of clinical oncology, 55:210-218, 2025
15. Yamashige D, Hijioka S, Shimizu Y, Yanagisawa A, Nakamura M, Hara K, Kitano M, Koshita S, Takikawa T, Kin T, Takenaka M, Hanada K, Ueki T, Itoi T, Yamada R, Ohtsuka T, Hirono S, Kanno A, Takeyama Y, Masamune A. Clinical impact of epithelial types on postoperative outcomes for intraductal papillary mucinous neoplasms: a multicenter retrospective study. Journal of gastroenterology, 60:658-670, 2025
16. Yamada R, Tanaka T, Shimada Y, Owa H, Nose K, Nakamura Y, Miwata T, Tsuboi J, Hara K, Hashigo S, Hashimoto A, Hijioka S, Okamoto K, Hirooka Y, Imai H, Inoue T, Iwata K, Kamada H, Kawaguchi S, Kawashima H, Kobayashi Y, Maruta A, Mukai T, Murabayashi T, Nakashima S, Naota H, Okumura F, Oya Y, Sato J, Sugimoto K, Hamaya Y, Tano S, Yoshinari M, Imai Y, Ogura T, Tamaru S, Nakagawa H. 6-mm vs 10-mm diameter fully covered self-expandable metal stents in patients with unresectable malignant distal bile duct stricture (COSMIC UNISON): study protocol for a multicenter, randomized controlled trial. Trials, 26:56, 2025
17. Toda Y, Ogura K, Morizane C, Satake T, Iwata S, Kobayashi E, Takemori T, Kondo H, Muramatsu S, Higashi T, Kawai A. Prognostic factors and management of elderly sarcoma in Japan: the population-based National Cancer Registry (NCR) in Japan. International journal of clinical oncology, 30:1018-1032, 2025
18. Okada M, Suzuki E, Morizane C, Ogawa G, Sano Y, Imaoka H, Kobayashi S, Ikeda M, Okano N, Miwa H, Todaka A, Shimizu S, Mizuno N, Satoi S, Sano K, Tobimatsu K, Katanuma A, Masutomi K, Okusaka T, Ozaka M, Ueno M. Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. Japanese journal of clinical oncology, 55:594-602, 2025
19. Hara H, Hijioka S, Yamashige D, Nagashio Y, Komori Y, Kuwada M, Fukuda S, Yagi S, Okamoto K, Agarie D, Chatto M, Okada M, Maruki Y, Morizane C, Ueno H, Saito Y, Yonemori K, Okusaka T. Clinical significance and efficacy of endoscopic ultrasound-guided tissue acquisition for para-aortic lymph node metastasis. Digestive endoscopy, 2025
20. Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kondo H, Kobayashi E, Higashi T, Kawai A. Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019. Scientific reports, 15:9960, 2025
21. Komiyama S, Okusaka T, Maruki Y, Ohba A, Nagashio Y, Kondo S, Hijioka S, Morizane C, Ueno H, Sukeda A, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Hiraoka N, Shimada K. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis. Internal medicine (Tokyo, Japan), 63:891-901, 2024
22. Hirano K, Maruki Y, Yamashige D, Kobayashi O, Shiotsuka M, Morizane C, Imamura T, Hiraoka N, Okusaka T. Two Cases of Disseminated Alveolar Echinococcosis: The Diagnosis, Management, and Differential Considerations for Liver Lesions. Internal medicine (Tokyo, Japan), 63:1247-1252, 2024
23. Yoo C, Lamarca A, Choi HJ, Vogel A, Pishvaian MJ, Goyal L, Ueno M, Märten A, Teufel M, Geng L, Morizane C. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future oncology (London, England), 20:1069-1077, 2024
24. Ishiwatari H, Ogura T, Hijioka S, Iwashita T, Matsubara S, Ishikawa K, Niiya F, Sato J, Okuda A, Ueno S, Nagashio Y, Maruki Y, Uemura S, Notsu A. EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a propensity score-matched case-control study. Gastrointestinal endoscopy, 100:66-75, 2024
25. Rikitake R, Mizushima Y, Yoshimoto S, Higashi T, Satake T, Morizane C, Kawai A. Current status of head and neck sarcomas in Japan in 2016-2019: an analysis using the national cancer registry. International journal of clinical oncology, 29:564-570, 2024
26. Harai S, Hijioka S, Yamada R, Ogura T, Fukasawa M, Okuda A, Horike H, Inoue D, Sekine M, Ishida Y, Koga T, Kitamura H, Tanaka Y, Yoshinari M, Kobayashi K, Chatto M, Yamashige D, Kawasaki Y, Nagashio Y, Okusaka T. Safety of biliary drainage with 6-mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. Journal of gastroenterology and hepatology, 39:1442-1449, 2024
27. Nakamura M, Sakon M, Sasako M, Okusaka T, Mukai H, Fujiwara K, Kunitoh H, Oba MS, Wada H, Hosokawa J, Takita A, Ikeda M. Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis. International journal of clinical oncology, 29:407-416, 2024
28. Kazmi SZ, Jung HS, Han Y, Yun WG, Cho YJ, Lee M, Kwon W, Castillo CF, Del Chiaro M, Marchegiani G, Goh BKP, Hijioka S, Majumder S, Nakai Y, Shin A, Jang JY. Systematic review on surveillance for non-resected branch-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology, 24:463-488, 2024
29. Takamizawa S, Koyama T, Sunami K, Sudo K, Hirata M, Kubo T, Tao K, Cho H, Narita Y, Kato K, Yamazaki N, Ohe Y, Okusaka T, Matsui Y, Ogawa C, Yonemori K, Yamamoto N. Identification of barriers to implementation of precision oncology in patients with rare cancers. Cancer science, 115:2023-2035, 2024
30. Agarie D, Hijioka S, Nagashio Y, Maruki Y, Chatto M, Saito Y, Okusaka T. The case of infected intra-abdominal hematoma complicating endoscopic ultrasound-guided tissue acquisition. Endoscopy, 56:E309-E310, 2024
31. Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO open, 9:102981, 2024
32. Hijioka S, Yamashige D, Esaki M, Honda G, Higuchi R, Masui T, Shimizu Y, Ohtsuka M, Kumamoto Y, Katanuma A, Gotohda N, Akita H, Unno M, Endo I, Yokoyama Y, Yamada S, Matsumoto I, Ohtsuka T, Hirano S, Yasuda H, Kawai M, Aoki T, Nakamura M, Hashimoto D, Rikiyama T, Horiguchi A, Fujii T, Mizuno S, Hanada K, Tani M, Hatori T, Ito T, Okuno M, Kagawa S, Tajima H, Ishii T, Sugimoto M, Onoe S, Takami H, Takada R, Miura T, Kurita Y, Kamei K, Mataki Y, Okazaki K, Takeyama Y, Yamaue H, Satoi S. Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies. Clinical gastroenterology and hepatology, 22:1416-1426.e5, 2024
33. Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, Kobayashi S, Furukawa M, Lee L, Satoh T, Sakai D, Ikeda M, Imaoka H, Miura A, Hatanaka Y, Yokota I, Nakamura Y, Yoshino T. Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England), 20:1901-1907, 2024
34. Ikeda M, Hijioka S, Ito T, Matsumoto S, Honma Y, Ueno M, Okano N, Aoki T, Furuse J. Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors. Japanese journal of clinical oncology, 54:880-886, 2024
35. Fukuda S, Hijioka S, Nagashio Y, Maruki Y, Chatto M, Saito Y, Okusaka T. Forward-viewing echoendoscope aids tissue acquisition via the afferent limb after pancreaticoduodenectomy. Endoscopy, 56:E366-E368, 2024
36. Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Żotkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, Oh DY. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 25:626-635, 2024
37. Okamoto K, Hijioka S, Nagashio Y, Okada M, Ohba A, Maruki Y, Kondo S, Morizane C, Ueno H, Okusaka T. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Japanese journal of clinical oncology, 54:887-894, 2024
38. Matsubayashi H, Morizane C. Familial and hereditary pancreatic cancer in Japan. Familial cancer, 23:365-372, 2024
39. Nakai Y, Matsubara S, Mukai T, Hamada T, Sasaki T, Ishiwatari H, Hijioka S, Shiomi H, Takenaka M, Iwashita T, Masuda A, Saito T, Isayama H, Yasuda I. Drainage for fluid collections post pancreatic surgery and acute pancreatitis: similar but different? Clinical endoscopy, 57:735-746, 2024
40. Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, Valle JW. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The lancet. Gastroenterology & hepatology, 9:694-704, 2024
41. Fukuda S, Hijioka S, Nagashio Y, Maruki Y, Ohba A, Agarie D, Hagiwara Y, Hara H, Okamoto K, Yamashige D, Yagi S, Kuwada M, Chatto M, Kondo S, Morizane C, Ueno H, Saito Y, Okusaka T. Feasibility and safety of a novel plastic stent designed specifically for endoscopic ultrasound-guided pancreatic duct drainage. Endoscopy international open, 12:E715-E722, 2024
42. Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M. Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22. Japanese journal of clinical oncology, 54:1071-1077, 2024
43. Hagiwara Y, Hijioka S, Nagashio Y, Maruki Y, Ohba A, Kawasaki Y, Takeshita K, Takasaki T, Agarie D, Hara H, Yagi S, Fukuda S, Kuwada M, Yamashige D, Okamoto K, Chatto M, Kondo S, Morizane C, Ueno H, Endo M, Sugawara S, Sone M, Saito Y, Tsuchiya K, Okusaka T. Efficacy of endoscopic ultrasound-guided gastroenterostomy using self-expandable metallic stent for afferent loop syndrome: A single-center retrospective study. Journal of gastroenterology and hepatology, 39:2136-2142, 2024
44. Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kobayashi E, Arakawa A, Ogawa C, Kato Y, Higashi T, Kawai A. Statistics of bone sarcoma in Japan: report from the population-based cancer registry in Japan. International journal of clinical oncology, 29:1209-1219, 2024
45. Sakamoto Y, Sakamoto T, Ohba A, Sasaki M, Kondo S, Morizane C, Ueno H, Saito Y, Arai Y, Okusaka T. Efficacy of hemostasis by gastroduodenal covered metal stent placement for hemorrhagic duodenal stenosis due to pancreatobiliary cancer invasion: a retrospective study. Clinical endoscopy, 57:628-636, 2024
46. Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future oncology (London, England), 20:2811-2822, 2024
47. Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, Furuse J, Ozaka M, Fukuda H, Ueno M. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Japanese journal of clinical oncology, 54:1214-1218, 2024
48. Kawasaki Y, Hijioka S, Nagashio Y, Ohba A, Maruki Y, Takeshita K, Takasaki T, Agarie D, Hagiwara Y, Hara H, Okamoto K, Yamashige D, Kondo S, Morizane C, Ueno H, Mizui T, Takamoto T, Nara S, Ban D, Esaki M, Saito Y, Hiraoka N, Okusaka T. Diagnostic performance of EUS-guided tissue acquisition for solid pancreatic lesions ≦10 mm. Endoscopic ultrasound, 13:115-122, 2024
49. Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Takemori T, Kondo H, Kobayashi E, Katoh Y, Higashi T, Kawai A. Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019. Japanese journal of clinical oncology, 54:1150-1157, 2024
50. Takeshita K, Hijioka S, Nagashio Y, Maruki Y, Ohba A, Kawasaki Y, Takasaki T, Yagi S, Agarie D, Hara H, Hagiwara Y, Yamashige D, Okamoto K, Fukuda S, Kuwada M, Chatto M, Kondo S, Morizane C, Ueno H, Saito Y, Okusaka T. Comparison of stent patency between EUS-guided hepaticogastrostomy with bridging and endoscopic transpapillary biliary drainage for hilar obstruction. Endoscopy international open, 12:E875-E886, 2024
51. Ogura T, Ishiwatari H, Hijioka S, Takeshita K, Sato J, Takenaka M, Fukunaga T, Omoto S, Fujimori N, Ohno A, Hatamaru K, Tamura T, Imai H, Yamada M, Hakoda A, Nishikawa H, Kitano M. Multicenter study comparing EUS-guided hepaticogastrostomy and ERCP for malignant biliary obstruction in patients with accessible papillae. Journal of hepato-biliary-pancreatic sciences, 31:680-687, 2024
52. Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer discovery, 14:2243-2261, 2024
53. Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, Nishina T, Todaka A, Okano N, Hara K, Nakai Y, Ohkawa K, Sasaki T, Sugimori K, Yokoyama N, Yamamoto K. A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clinical cancer research, 30:3990-3995, 2024
54. Tezuka S, Ozaka M, Furuse J, Yokoyama M, Uemura K, Sano Y, Nakachi K, Imaoka H, Unno M, Shirakawa H, Shimizu S, Kato N, Kojima Y, Sano K, Kobayashi S, Terashima T, Morizane C, Ikeda M, Ueno M. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407. Pancreatology, 24:909-916, 2024
55. Yagi S, Hijioka S, Okamoto K, Nagashio Y, Chatto M, Saito Y, Okusaka T. Successful gastroduodenal stenting using the endoscopic ultrasound-guided rendezvous technique by Treitz ligament puncture. Endoscopy, 56:E653-E655, 2024
56. Ishida M, Fujii T, Kishiwada M, Shibuya K, Satoi S, Ueno M, Nakata K, Takano S, Uchida K, Ohike N, Masugi Y, Furukawa T, Hirabayashi K, Fukushima N, Yi SQ, Isayama H, Itoi T, Ohtsuka T, Okusaka T, Inoue D, Kitagawa H, Takaori K, Tani M, Nagakawa Y, Yoshitomi H, Unno M, Takeyama Y. Japanese classification of pancreatic carcinoma by the Japan Pancreas Society: Eighth edition. Journal of hepato-biliary-pancreatic sciences, 31:755-768, 2024
57. Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, Ikeda M, Sasaki M, Furuse J, Okano N, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology, 42:3207-3217, 2024
58. Ohtsuka T, Maguchi H, Tokunaga S, Hijioka S, Takayama Y, Koshita S, Hanada K, Sudo K, Uehara H, Tanno S, Tada M, Kimura W, Nakamura M, Kin T, Kamata K, Masamune A, Iwashita T, Akahoshi K, Ueki T, Okamura K, Kato H, Kumagi T, Kawabe K, Yoshida K, Mukai T, Sakagami J, Hirono S, Abue M, Nakafusa T, Morita M, Shimosegawa T, Tanaka M. Prospective multicenter surveillance study of branch-duct intraductal papillary mucinous neoplasm of the pancreas; risk of dual carcinogenesis. Pancreatology, 24:1141-1151, 2024
59. Takeshita K, Hijioka S, Nagashio Y, Hara H, Agarie D, Kawasaki Y, Takasaki T, Yagi S, Hagiwara Y, Okamoto K, Yamashige D, Fukuda S, Kuwada M, Komori Y, Okada M, Maruki Y, Morizane C, Ueno H, Yatabe Y, Okusaka T. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endoscopic Ultrasound-Guided Tissue Acquisition Using a 19G Needle from Primary and Metastatic Lesions in Pancreatic Cancer with Metastatic Lesions: The PRIMATE Study. Diseases (Basel, Switzerland), 12:182, 2024
60. Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, Muramatsu S, Kondo H, Kobayashi E, Higashi T, Kawai A. Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan. Japanese journal of clinical oncology, 54:1281-1287, 2024
61. Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, Yoshino T, Ikeda M, Morizane C. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. British journal of cancer, 131:1237-1245, 2024
62. Fukuda S, Hijioka S, Nagashio Y, Yamashige D, Agarie D, Hagiwara Y, Okamoto K, Yagi S, Komori Y, Kuwada M, Maruki Y, Morizane C, Ueno H, Hiraoka N, Tsuchiya K, Okusaka T. Utility of Transpapillary Biopsy and Endoscopic Ultrasound-Guided Tissue Acquisition for Comprehensive Genome Profiling of Unresectable Biliary Tract Cancer. Cancers, 16:2819, 2024
63. Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M. 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). Journal of hepato-biliary-pancreatic sciences, 31:886-896, 2024
64. Ueno M, Morizane C, Ikeda M, Ozaka M, Nagashima F, Kataoka T, Mizusawa J, Ohba A, Kobayashi S, Imaoka H, Kasuga A, Okano N, Nagasaka Y, Sasaki M, Furuse J, Okusaka T. Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE). ESMO open, 9:103919, 2024
65. Kawasaki Y, Hijioka S, Nagashio Y, Chatto M, Okusaka T, Saito Y. Gas embolism in double-balloon endoscopic retrograde cholangiography with carbon dioxide insufflation. Endoscopy, 56:E951-E952, 2024
66. Satake T, Morizane C, Okada M, Nishioka M, Hiraoka N, Nara S, Kakegawa T, Kobayashi M, Koyama K, Esaki M, Okusaka T. Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy. Cancer medicine, 13:e70474, 2024